Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose aflibercept versus standard-dose aflibercept in neovascular age-related macular degeneration
CTR20202429Phase 3Completed
- Sponsor
- Bayer
- Start
- Dec 2020
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of aflibercept in exudative macular degeneration, sponsored by Bayer. Started Dec 2020; status: completed.
02
Drugs
aflibercept
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on CTR20202429.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20202429.